logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
Showing 1 - 19 of 19 Items
Showing 1 - 19 of 19 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Video

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Protocol
Conference Material
|
Slide Presentation
Technical Report
|
Evidence Brief
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Short Report
Journal Article
|
Protocol
Research & Publication Resources
|
Research Protocol
Journal Article
|
Research
Conference Material
|
Abstract
Conference Material
|
Video

Pregnancy outcomes in patients undergoing drug-resistant tuberculosis treatment in two closely monitored cohorts

Lachenal N, Hewison CCH, Berry C, Mitnick CD, 
Conference Material
|
Slide Presentation
Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

endTB Clinical Trial: Design, efficacy, safety & linezolid dose-reduction randomization results

endTB Study Group
2023-11-15 • The Union World Conference on Lung Health 2023
2023-11-15 • The Union World Conference on Lung Health 2023

High-quality evidence on new, all-oral, shortened MDR-TB regimens

endTB Study Group
2023-11-15
2023-11-15
Each year there are approximately 500,000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide, but only a tiny fraction is successfully treated. The endTB trial, led by Méde...

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...

Does One Size Fit All? Drug Resistance and Standard Treatments: Results of Six Tuberculosis Programmes in Former Soviet Countries

Bonnet MMB, Sizaire V, Kebede YYK, Janin A, Doshetov D,  et al.
2005-10-01 • International Journal of Tuberculosis and Lung Disease
2005-10-01 • International Journal of Tuberculosis and Lung Disease
SETTING: After the collapse of the Soviet Union, countries in the region faced a dramatic increase in tuberculosis cases and the emergence of drug resistance. OBJECTIVE: To discuss the r...

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH,  et al.
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...

Culture conversion in patients treated with bedaquiline and/or delamanid: A prospective multi-country study

Franke MF, Khan PY, Hewison CCH, Khan UT, Huerga H,  et al.
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
BACKGROUND
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...

Pregnancy outcomes in patients undergoing drug-resistant tuberculosis treatment in two closely monitored cohorts

Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
Drug-resistant tuberculosis (DR-TB) carries significant morbidity and mortality risk. Care of DR-TB in pregnancy is even more challenging. A recent meta-analysis examini...
Ahmed SM, 
et al.
2022-06-10 • MSF Scientific Days International 2022
2022-06-10 • MSF Scientific Days International 2022

Pregnancy outcomes in patients undergoing drug-resistant tuberculosis treatment in two closely monitored cohorts

Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022

Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

Cox V, Brigden G, Crespo RH, Lessem E, Lynch S,  et al.
2018-04-01 • International Journal of Tuberculosis and Lung Disease
2018-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 201...